| ［1］ |
International Union Against Cancer （UICC）. TNM classification of malignant tumors［M］. 7th ed. New York: Wiley-Liss， 2009.
|
| ［2］ |
Guyatt G， Oxman AD， Akl EA， et al. GRADE guidelines: 1.Introduction-GRADE evidence profiles and summary of findings tables［J］. J Clin Epidemiol，2011，64（4）:383-394. DOI:10.1016/j.jclinepi.2010.04.026.
|
| ［3］ |
Balshem H， Helfand M， Schünemann HJ， et al. GRADE guidelines: 3.Rating the quality of evidence［J］. J Clin Epidemiol， 2011，64（4）:401-406. DOI:10.1016/j.jclinepi.2010.07.015.
|
| ［4］ |
ASCO Guidelines Methodology Manual［EB/OL］.（2021-09-09）［2023-12-15］. https://www.asco.org/sites/new-www. asco.org/files/contentfiles/advocacy-and-policy/documents/ Guidelines-Methodology-Manual_0.pdf.
|
| ［5］ |
Nakeeb A， Pitt HA， Sohn TA， et al. Cholangiocarcinoma. A spectrum of intrahepatic， perihilar， and distal tumors［J］. Ann Surg，1996，224（4）:463-475. DOI:10.1097/00000658-199610000-00005.
|
| ［6］ |
The WHO Classification of Tumors Editorial Board. WHO classification of tumours of digestive system tumors［M］. 5th ed.Lyon: IARC Press，2019.
|
| ［7］ |
Ebata T， Kosuge T， Hirano S， et al. Proposal to modify the International Union Against Cancer staging system for perihilar cholangiocarcinomas［J］. Br J Surg，2014，101（2）:79-88. DOI:10.1002/bjs.9379.
|
| ［8］ |
Boonstra K， Weersma RK， van Erpecum KJ， et al. Population-based epidemiology， malignancy risk， and outcome of primary sclerosing cholangitis［J］. Hepatology，2013，58（6）:2045-2055. DOI:10.1002/hep.26565.
|
| ［9］ |
Brindley PJ， Bachini M， Ilyas SI， et al. Cholangiocarcinoma［J］. Nat Rev Dis Primers，2021，7（1）:65. DOI:10.1038/s415 72-021-00300-2.
|
| ［10］ |
Zhang Y， Ma Z， Li C， et al. The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers［J］. Nat Commun，2022，13（1）:3061. DOI: 10.1038/s41467-022-30708-7.
|
| ［11］ |
Clements O， Eliahoo J， Kim JU， et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and metaanalysis［J］. J Hepatol，2020，72（1）:95-103. DOI:10.1016/j.jhep.2019.09.007.
|
| ［12］ |
Lee BS， Cha BH， Park EC， et al. Risk factors for perihilar cholangiocarcinoma: a hospital-based case-control study［J］. Liver Int，2015，35（3）:1048-1053. DOI:10.1111/liv.12618.
|
| ［13］ |
Welzel TM， Graubard BI， El-Serag HB， et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study［J］. Clin Gastroenterol Hepatol，2007，5（10）:1221-1228. DOI: 10.1016/j.cgh.2007.05.020.
|
| ［14］ |
Toyohara T， Nakazawa T， Zakharia K， et al. IgG4-related sclerosing cholangitis complicated with cholangiocarcinoma and detected by forkhead box P3 immunohistochemical staining［J］. Intern Med，2021，60（6）:859-866. DOI:10.2169/ internalmedicine.5920-20.
|
| ［15］ |
Kurita Y， Fujita Y， Sekino Y， et al. IgG4-related sclerosing cholangitis may be a risk factor for cancer［J］. J Hepatobiliary Pancreat Sci，2021，28（6）:524-532. DOI:10.1002/jhbp.957.
|
| ［16］ |
Roukounakis NE， Kuhn JA， McCarty TM. Association of an abnormal pancreaticobiliary junction with biliary tract cancers［J］.Proc （Bayl Univ Med Cent）， 2000， 13（1）: 11-13. DOI:10.1080/08998 280.2000.11927636.
|
| ［17］ |
Abdel Wahab M， Mostafa M， Salah T， et al. Epidemiology of hilar cholangiocarcinoma in Egypt: single center study［J］.Hepatogastroenterology，2007，54（78）:1626-1631.
|
| ［18］ |
Robbins S， Chuang VP， Hersh T. The development of hepatobiliary cancer in a carrier of Salmonella typhus［J］. Am J Gastroenterol，1988，83（6）:675-678.
|
| ［19］ |
Xiao M， Gao Y， Wang Y. Helicobacter species infection may be associated with cholangiocarcinoma: a meta-analysis［J］. Int J Clin Pract， 2014， 68（2）: 262-270. DOI: 10.1111/ijcp.12264.
|
| ［20］ |
Segura-López FK， Güitrón-Cantú A， Torres J. Association between Helicobacter spp. infections and hepatobiliary malignancies:a review［J］. World J Gastroenterol， 2015， 21 （5）:1414-1423.DOI:10.3748/wjg.v21.i5.1414.
|
| ［21］ |
Rushbrook SM， Kendall TJ， Zen Y， et al. British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma［J］. Gut， 2023， 73（1）: 16-46. DOI:10.1136/gutjnl-2023-330029.
|
| ［22］ |
毛谅，杨翼飞，艾力西尔·艾拜都拉，等 . 基于多学科诊断与治疗的肝门部胆管癌外科手术疗效和预后影响因素分析［J］. 中华消化外科杂志，2023，22（7）:873-883. DOI:10.3760/cma. j.cn115610-20230509-00200.
|
| ［23］ |
La’ulu SL， Roberts WL. Performance characteristics of five automated CA 19-9 assays［J］. Am J Clin Pathol， 2007， 127 （3）:436-440. DOI:10.1309/H52VET3M6P7GYWG1.
|
| ［24］ |
Patel AH， Harnois DM， Klee GG， et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis［J］. Am J Gastroenterol， 2000， 95（1）: 204-207.DOI: 10.1111/j. 1572-0241.2000.01685.x.
|
| ［25］ |
Nguyen-tat M， Gamstätter T， Marquardt JU， et al. IgG4-related sclerosing cholangitis mimicking cholangiocarcinoma［J］. Z Gastroenterol，2012，50（9）:1008-1012. DOI:10.1055/ s-0031-1299451.
|
| ［26］ |
Erdogan D， Kloek JJ， ten Kate FJ， et al. Immunoglobulin G4related sclerosing cholangitis in patients resected for presumed malignant bile duct strictures［J］. Br J Surg，2008，95 （6）:727-734. DOI:10.1002/bjs.6057.
|
| ［27］ |
Nakazawa T， Naitoh I， Hayashi K， et al. Diagnosis of IgG4-related sclerosing cholangitis［J］. World J Gastroenterol，2013， 19（43）:7661-7670. DOI:10.3748/wjg.v19.i43.7661.
|
| ［28］ |
Khan SA， Davidson BR， Goldin RD， et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update［J］.Gut，2012，61（12）:1657-1669. DOI:10.1136/gutjnl-2011-301748.
|
| ［29］ |
Kamisawa T， Nakazawa T， Tazuma S， et al. Clinical practice guidelines for IgG4-related sclerosing cholangitis［J］. J Hepatobiliary Pancreat Sci，2019，26（1）:9-42. DOI:10.1002/ jhbp.596.
|
| ［30］ |
王宏光， 罗漫. 肝门部胆管癌的术前评估和术中导航研究进展［J］. 中华消化外科杂志，2024，23（7）:906-911. DOI:10.37 60/cma.j.cn115610-20240612-00291.
|
| ［31］ |
Elbanna KY， Kielar AZ. Computed tomography versus magnetic resonance imaging for hepatic lesion characterization/diagnosis［J］.Clin Liver Dis （Hoboken），2021，17（3）: 159-164. DOI:10.1002/cld.1089.
|
| ［32］ |
Suthar M， Purohit S， Bhargav V， et al. Role of MRCP in differentiation of benign and malignant causes of biliary obstruction［J］. J Clin Diagn Res，2015，9（11）:TC08-12. DOI:10.7860/ JCDR/2015/14174.6771.
|
| ［33］ |
Masselli G， Gualdi G. Hilar cholangiocarcinoma: MRI/MRCP in staging and treatment planning［J］. Abdom Imaging，2008， 33（4）:444-451. DOI:10.1007/s00261-007-9281-6.
|
| ［34］ |
Burnett AS， Calvert TJ， Chokshi RJ. Sensitivity of endoscopic retrograde cholangiopancreatography standard cytology: 10-y review of the literature［J］. J Surg Res， 2013， 184（1）: 304-311. DOI:10.1016/j.jss.2013.06.028.
|
| ［35］ |
Yoon SB， Moon SH， Ko SW， et al. Brush cytology， forceps biopsy，or endoscopic ultrasound-guided sampling for diagnosis of bile duct cancer: a meta-analysis［J］. Dig Dis Sci， 2022，67（7）:3284-3297.DOI:10.1007/s10620-021-07138-4.
|
| ［36］ |
Al Nakshabandi A， Ali FS， Albustami I， et al. Biliary drainage in hilar and perihilar cholangiocarcinoma: 25-year experience at a tertiary cancer center［J］. Gastrointest Endosc， 2024，99（6）:938-949.e15.DOI:10.1016/j.gie.2023.12.006.
|
| ［37］ |
Menzel J， Poremba C， Dietl KH， et al. Preoperative diagnosis of bile duct strictures--comparison of intraductal ultrasonography with conventional endosonography［J］. Scand J Gastroenterol， 2000， 35（1）:77-82. DOI:10.1080/003655200750024579.
|
| ［38］ |
Inui K， Yoshino J， Okushima K， et al. Intraductal EUS［J］.Gastrointest Endosc，2002，56（4 Suppl）:S58-S62. DOI:10. 1016/s0016-5107（02）70087-4.
|
| ［39］ |
Kuroiwa M， Goto H， Hirooka Y， et al. Intraductal ultrasonography for the diagnosis of proximal invasion in extrahepatic bile duct cancer［J］.J Gastroenterol Hepatol， 1998， 13（7）:715-719. DOI:10.1111/j.1440-1746.1998.tb00719.x.
|
| ［40］ |
Ito K， Sakamoto Y， Isayama H， et al. The impact of MDCT and endoscopic transpapillary mapping biopsy to predict longitudinal spread of extrahepatic cholangiocarcinoma［J］. J Gastrointest Surg，2018，22（9）:1528-1537. DOI:10.1007/ s11605-018-3793-y.
|
| ［41］ |
Fukasawa Y， Takano S， Fukasawa M， et al. Form-vessel classification of cholangioscopy findings to diagnose biliary tract carcinoma’s superficial spread［J］. Int J Mol Sci， 2020，21（9）:3311. DOI:10.3390/ijms21093311.
|
| ［42］ |
Breitenstein S， Apestegui C， Clavien PA. Positron emission tomography （PET） for cholangiocarcinoma［J］. HPB （Oxford），2008，10（2）:120-121. DOI:10.1080/13651820801992583.
|
| ［43］ |
Kim JY， Kim MH， Lee TY， et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging［J］. Am J Gastroenterol，2008， 103（5）: 1145-1151. DOI:10.1111/j.1572-0241.2007.01710.x.
|
| ［44］ |
Bismuth H， Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver［J］. Surg Gynecol Obstet，1975，140（2）:170-178.
|
| ［45］ |
董家鸿，项灿宏，石军，等. 以围肝门切除为本的肝门部胆管癌治愈性切除术的临床疗效［J］. 中华消化外科杂志， 2017， 16（10）:1053-1060. DOI: 10.3760/cma.j.issn.1673-9752. 2017.10.014.
|
| ［46］ |
Jarnagin WR， Fong Y， DeMatteo RP， et al. Staging， resectability， and outcome in 225 patients with hilar cholangiocarcinoma［J］. Ann Surg，2001， 234（4）: 507-519. DOI: 10.10 97/00000658-200110000-00010.
|
| ［47］ |
Lee AJ， Chun YS. Intrahepatic cholangiocarcinoma: the AJCC/UICC 8th edition updates［J］. Chin Clin Oncol，2018，7 （5）:52. DOI:10.21037/cco.2018.07.03.
|
| ［48］ |
WHO Classification of Tumours Editorial Board. WHO classfication of tumours: digestive system tumours［M］. 5th ed. Lyon: IARC Press，2019.
|
| ［49］ |
Nagtegaal ID， Odze RD， Klimstra D， et al. The 2019 WHO classification of tumours of the digestive system［J］. Histopathology，2020，76（2）:182-188. DOI:10.1111/his.13 975.
|
| ［50］ |
Gopal P， Robert ME， Zhang X. Cholangiocarcinoma: pathologic and molecular classification in the era of precision medicine［J］. Arch Pathol Lab Med， 2024， 148（3）: 359-370. DOI:10.5858/arpa.2022-0537-RA.
|
| ［51］ |
Igami T， Nagino M， Oda K， et al. Clinicopathologic study of cholangiocarcinoma with superficial spread［J］. Ann Surg， 2009，249（2）: 296-302. DOI: 10.1097/SLA. 0b013e318190 a647.
|
| ［52］ |
Jin S， Jiang N， Zhao JM， et al. Pattern and extent of intrahepatic infiltration of perihilar cholangiocarcinoma-a case-control study based on liver panoramic digital pathology［J］. Int J Surg，2024（2024-08-14）［2025-01-06］. https://pub med.ncbi.nlm.nih.gov/39166939/.DOI:10.1097/JS9.000 0000000002040. ［published online ahead of print］.
|
| ［53］ |
Kimura N， Young AL， Toyoki Y， et al. Radical operation for hilar cholangiocarcinoma in comparable Eastern and Western centers:outcome analysis and prognostic factors［J］. Surgery， 2017， 162（3）:500-514. DOI: 10.1016/j. surg.2017.03.017.
|
| ［54］ |
Zhang XF， Beal EW， Chakedis J， et al. Defining early recurrence of hilar cholangiocarcinoma after curative-intent surgery: a multiinstitutional study from the US extrahepatic biliary malignancy consortium［J］. World J Surg， 2018， 42（9）:2919-2929. DOI:10.1007/s00268-018-4530-0.
|
| ［55］ |
Ito T， Ebata T， Yokoyama Y， et al. The pathologic correlation between liver and portal vein invasion in perihilar cholangiocarcinoma:evaluating the oncologic rationale for the American Joint Committee on Cancer definitions of T2 and T3 tumors［J］. World J Surg， 2014，38（12）: 3215-3221. DOI:10.1007/s00268-014-2719-4.
|
| ［56］ |
van Keulen AM， Buettner S， Erdmann JI， et al. Multivariable prediction model for both 90-day mortality and long-term survival for individual patients with perihilar cholangiocarcinoma: does the predicted survival justify the surgical risk？［J］. Br J Surg， 2023，110（5）: 599-605. DOI: 10. 1093/bjs/znad057.
|
| ［57］ |
Nagino M， Ebata T， Yokoyama Y， et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections［J］. Ann Surg， 2013，258（1）:129-140. DOI:10.1097/SLA.0b013e3182708 b57.
|
| ［58］ |
Lv TR， Ma WJ， Liu F， et al. The significance of peri-neural invasion in patients with resected hilar cholangiocarcinoma: a singlecenter experience in China［J］. Asian J Surg， 2024 47（1）:274-280.DOI:10.1016/j.asjsur.2023.08.110.
|
| ［59］ |
Jin S， Lin MY， Xiang CH， et al. The status of liver margin in perihilar cholangiocarcinoma: a multicenter study［J］. Ann Surg，2024（2024-10-21）［2025-01-06］. https://pubmed.ncbi. nlm.nih.gov/39431564/.DOI:10.1097/SLA.0000000000006571. ［published online ahead of print］.
|
| ［60］ |
Ratti F， Marino R， Pedica F， et al. Radial and longitudinal margins in surgery of perihilar cholangiocarcinoma: when R1 definition is associated with different prognosis［J］. Surgery， 2023， 174（3）: 447-456. DOI: 10.1016/j. surg. 2023.05.014.
|
| ［61］ |
Shinohara K， Ebata T， Shimoyama Y， et al. A study on radial margin status in resected perihilar cholangiocarcinoma［J］. Ann Surg，2021，273（3）:572-578. DOI:10.1097/SLA.0000000000003305.
|
| ［62］ |
Endo I， House MG， Klimstra DS， et al. Clinical significance of intraoperative bile duct margin assessment for hilar cholangiocarcinoma［J］. Ann Surg Oncol，2008，15（8）:2104-2112.DOI:10.1245/s10434-008-0003-2.
|
| ［63］ |
Higuchi R， Ota T， Araida T， et al. Prognostic relevance of ductal margins in operative resection of bile duct cancer［J］. Surgery，2010，148（1）:7-14. DOI:10.1016/j.surg.2009.11.018.
|
| ［64］ |
Konishi M， Iwasaki M， Ochiai A， et al. Clinical impact of intraoperative histological examination of the ductal resection margin in extrahepatic cholangiocarcinoma［J］. Br J Surg，2010，97（9）:1363-1368. DOI:10.1002/bjs.7122.
|
| ［65］ |
Mansour JC， Aloia TA， Crane CH， et al. Hilar cholangiocarcinoma:expert consensus statement［J］. HPB （Oxford），2015， 17（8）:691-699.DOI:10.1111/hpb.12450.
|
| ［66］ |
Poruk KE， Pawlik TM， Weiss MJ. Perioperative management of hilar cholangiocarcinoma［J］. J Gastrointest Surg， 2015， 19（10）:1889-1899.DOI:10.1007/s11605-015-2854-8.
|
| ［67］ |
Hirano S， Tanaka E， Shichinohe T， et al. Treatment strategy for hilar cholangiocarcinoma， with special reference to the limits of ductal resection in right-sided hepatectomies［J］. J Hepatobiliary Pancreat Surg，2007，14（5）:429-433. DOI: 10.1007/s00534-006-1190-5.
|
| ［68］ |
Nagino M， Nimura Y， Nishio H， et al. Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases［J］. Ann Surg，2010，252（1）:115-123. DOI: 10.1097/SLA.0b013e3181e463a7.
|
| ［69］ |
Yokoyama Y， Ebata T， Igami T， et al. The predictive value of indocyanine green clearance in future liver remnant for posthepatectomy liver failure following hepatectomy with extrahepatic bile duct resection［J］. World J Surg，2016，40 （6）:1440-1447. DOI:10.1007/s00268-016-3441-1.
|
| ［70］ |
Horisberger K， Rössler F， Oberkofler CE， et al. The value of intraoperative dynamic liver function test ICG in predicting postoperative complications in patients undergoing staged hepatectomy: a pilot study［J］. Langenbecks Arch Surg，2023，408（1）:264. DOI:10.1007/s00423-023-02983-5.
|
| ［71］ |
Yokoyama Y， Nishio H， Ebata T， et al. Value of indocyanine green clearance of the future liver remnant in predicting outcome after resection for biliary cancer［J］. Br J Surg，2010， 97（8）:1260-1268.DOI:10.1002/bjs.7084.
|
| ［72］ |
Lopez-Lopez V， Gongora E， Miura K， et al. Multimodal prehabilitation program in patients with resectable perihilar cholangiocarcinoma: keypoints for an implementation protocol and literature review［J］. Langenbecks Arch Surg，2024， 409（1）:61.DOI:10.1007/s00423-024-03251-w.
|
| ［73］ |
Hau HM， Devantier M， Jahn N， et al. Impact of body mass index on tumor recurrence in patients undergoing liver resection for perihilar cholangiocarcinoma （pCCA）［J］. Cancers （Basel），2021，13（19）:4772.DOI:10.3390/cancers13194772.
|
| ［74］ |
She WH， Cheung TT， Ma KW， et al. Defining the optimal bilirubin level before hepatectomy for hilar cholangiocarcinoma［J］. BMC Cancer，2020，20（1）:914. DOI:10.1186/s12 885-020-07385-0.
|
| ［75］ |
Wiggers JK， Groot Koerkamp B， Cieslak KP， et al. Postoperative mortality after liver resection for perihilar cholangiocarcinoma:development of a risk score and importance of biliary drainage of the future liver remnant［J］. J Am Coll Surg， 2016， 223（2）: 321-331. e1.DOI: 10.1016/j. jamcollsurg.2016.03.035.
|
| ［76］ |
Rerknimitr R， Angsuwatcharakon P， Ratanachu-ek T， et al. Asia-Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma［J］. J Gastroenterol Hepatol，2013，28（4）:593-607. DOI:10. 1111/jgh.12128.
|
| ［77］ |
Olthof PB， Wiggers JK， Groot Koerkamp B， et al. Postoperative liver failure risk score: identifying patients with resectable perihilar cholangiocarcinoma who can benefit from portal vein embolization［J］. J Am Coll Surg， 2017， 225（3）: 387-394.DOI:10.1016/j.jamcollsurg.2017.06.007.
|
| ［78］ |
Hewitt DB， Brown ZJ， Pawlik TM. Current perspectives on the surgical management of perihilar cholangiocarcinoma［J］. Cancers（Basel），2022，14（9）:2208. DOI:10.3390/cancers 14092208.
|
| ［79］ |
Padillo FJ， Andicoberry B， Naranjo A， et al. Anorexia and the effect of internal biliary drainage on food intake in patients with obstructive jaundice［J］. J Am Coll Surg，2001， 192（5）:584-590. DOI:10.1016/s1072-7515（01）00841-9.
|
| ［80］ |
Mehrabi A， Khajeh E， Ghamarnejad O， et al. Meta-analysis of the efficacy of preoperative biliary drainage in patients undergoing liver resection for perihilar cholangiocarcinoma［J］. Eur J Radiol，2020，125:108897. DOI:10.1016/j.ejrad. 2020.108897.
|
| ［81］ |
Ribero D， Zimmitti G， Aloia TA， et al. Preoperative cholangitis and future liver remnant volume determine the risk of liver failure in patients undergoing resection for hilar cholangiocarcinoma［J］. J Am Coll Surg， 2016， 223（1）: 87-97. DOI:10.1016/j.jamcollsurg.2016.01.060.
|
| ［82］ |
Dumonceau JM， Tringali A， Papanikolaou IS， et al. Endoscopic biliary stenting: indications， choice of stents， and results:European Society of Gastrointestinal Endoscopy （ESGE） clinical guidelineupdated October 2017［J］. Endoscopy， 2018，50（9）:910-930.DOI:10.1055/a-0659-9864.
|
| ［83］ |
Al Mahjoub A， Menahem B， Fohlen A， et al. Preoperative biliary drainage in patients with resectable perihilar cholangiocarcinoma: is percutaneous transhepatic biliary drainage safer and more effective than endoscopic biliary drainage？ A meta-analysis［J］. J Vasc Interv Radiol，2017，28（4）: 576-582. DOI:10.1016/j.jvir.2016.12.1218.
|
| ［84］ |
Iacono C， Ruzzenente A， Campagnaro T， et al. Role of preoperative biliary drainage in jaundiced patients who are candidates for pancreatoduodenectomy or hepatic resection: highlights and drawbacks［J］. Ann Surg，2013，257（2）: 191-204. DOI:10.1097/SLA.0b013e31826f4b0e.
|
| ［85］ |
Komaya K， Ebata T， Yokoyama Y， et al. Verification of the oncologic inferiority of percutaneous biliary drainage to endoscopic drainage:A propensity score matching analysis of resectable perihilar cholangiocarcinoma［J］. Surgery， 2017，161（2）:394-404. DOI:10.1016/j.surg.2016.08.008.
|
| ［86］ |
Kawashima H， Itoh A， Ohno E， et al. Preoperative endoscopic nasobiliary drainage in 164 consecutive patients with suspected perihilar cholangiocarcinoma: a retrospective study of efficacy and risk factors related to complications［J］. Ann Surg， 2013， 257（1）: 121-127. DOI: 10.1097/SLA. 0b 013e318262b2e9.
|
| ［87］ |
Coelen R， Roos E， Wiggers JK， et al. Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre， randomised controlled trial［J］.Lancet Gastroenterol Hepatol， 2018， 3（10）: 681-690. DOI:10.1016/S2468-1253（18）30234-6.
|
| ［88］ |
Wang L， Lin N， Xin F， et al. A systematic review of the comparison of the incidence of seeding metastasis between endoscopic biliary drainage and percutaneous transhepatic biliary drainage for resectable malignant biliary obstruction［J］. World J Surg Oncol， 2019， 17（1）:116. DOI:10.11 86/s12957-019-1656-y.
|
| ［89］ |
Miura S， Kanno A， Masamune A， et al. Bismuth classification is associated with the requirement for multiple biliary drainage in preoperative patients with malignant perihilar biliary stricture［J］. Surg Endosc， 2015， 29（7）: 1862-1870. DOI: 10.1007/s00464-014-3878-y.
|
| ［90］ |
Wiggers JK， Groot Koerkamp B， Coelen RJ， et al. Preoperative biliary drainage in perihilar cholangiocarcinoma: identifying patients who require percutaneous drainage after failed endoscopic drainage［J］.Endoscopy， 2015， 47（12）: 1124-1131. DOI: 10.1055/s-0034-1392559.
|
| ［91］ |
Kloek JJ， van der Gaag NA， Aziz Y， et al. Endoscopic and percutaneous preoperative biliary drainage in patients with suspected hilar cholangiocarcinoma［J］. J Gastrointest Surg， 2010，14（1）:119-125.DOI:10.1007/s11605-009-1009-1.
|
| ［92］ |
Dar FS， Abbas Z， Ahmed I， et al. National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma［J］. World J Gastroenter ol，2024，30（9）:1018-1042. DOI:10.374 8/wjg.v30.i9.1018.
|
| ［93］ |
Takahashi Y， Sasahira N， Sasaki T， et al. The role of stent placement above the papilla （inside-stent） as a bridging therapy for perihilar biliary malignancy: an initial experience［J］. Surg Today，2021，51（11）:1795-1804. DOI:10.1007/ s00595-021-02268-8.
|
| ［94］ |
Coelen RJ， Huiskens J， Olthof PB， et al. Compliance with evidence-based multidisciplinary guidelines on perihilar cholangiocarcinoma［J］. United European Gastroenterol J，2017，5（4）:519-526. DOI:10.1177/2050640616673517.
|
| ［95］ |
Ishiwatari H， Kawabata T， Kawashima H， et al. Clinical outcomes of inside stents and conventional plastic stents as bridge-to-surgery options for malignant hilar biliary obstruction［J］. Dig Dis Sci， 2023，68（4）: 1139-1147. DOI: 10.10 07/s10620-022-07718-y.
|
| ［96］ |
Mori H， Kawashima H， Ohno E， et al. Comparison of an inside stent and a fully covered self-expandable metallic stent as preoperative biliary drainage for patients with resectable perihilar cholangiocarcinoma［J］. Can J Gastroenterol Hepatol，2022，2022:3005210. DOI:10.1155/2022/3005210.
|
| ［97］ |
Seyama Y， Kubota K， Sano K， et al. Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate［J］. Ann Surg，2003，238 （1）:73-83. DOI:10.1097/01.SLA.0000074960.55004.72.
|
| ［98］ |
van Gulik TM， Kloek JJ， Ruys AT， et al. Multidisciplinary management of hilar cholangiocarcinoma （Klatskin tumor）: extended resection is associated with improved survival［J］. Eur J Surg Oncol，2011，37（1）:65-71. DOI:10.1016/j.ejso.2010.11.008.
|
| ［99］ |
Olthof PB， Aldrighetti L， Alikhanov R， et al. Portal vein embolization is associated with reduced liver failure and mortality in highrisk resections for perihilar cholangiocarcinoma［J］. Ann Surg Oncol，2020，27（7）:2311-2318. DOI: 10.1245/s10434-020-08258-3.
|
| ［100］ |
Wu B， Huang X， Ren Z， et al. Comparing iodized oil with polyvinyl alcohol for portal vein embolization in promoting liver remnant increase before partial hepatectomy［J］. Asian J Surg，2024，47（2）:874-879. DOI:10.1016/j.asjsur. 2023.10.040.
|
| ［101］ |
Franken LC， Schreuder AM， Roos E， et al. Morbidity and mortality after major liver resection in patients with perihilar cholangiocarcinoma: a systematic review and meta-analysis［J］.Surgery， 2019， 165（5）:918-928. DOI:10.1016/j. surg.2019.01.010.
|
| ［102］ |
Narula N， Aloia TA. Portal vein embolization in extended liver resection［J］. Langenbecks Arch Surg，2017，402（5）:727-735.DOI:10.1007/s00423-017-1591-8.
|
| ［103］ |
Hasselgren K， Sandström P， Røsok BI， et al. Future liver remnant（FLR） increase in patients with colorectal liver metastases is highest the first week after portal vein occlusion: FLR increase in patients with CRLM is highest the first week after PVO［J］. J Gastrointest Surg，2019，23（3）: 556-562. DOI:10.1007/s11605-018-4031-3.
|
| ［104］ |
Leung U， Simpson AL， Araujo RL， et al. Remnant growth rate after portal vein embolization is a good early predictor of posthepatectomy liver failure［J］. J Am Coll Surg，2014， 219（4）:620-630.DOI:10.1016/j.jamcollsurg.2014.04.022.
|
| ［105］ |
张琪佳，王开宇，张跃伟，等. 动态单光子发射计算机断层扫描99Tcm-乙二烯三胺五醋酸-半乳糖人血清白蛋白显像技术评估肝门部胆管癌门静脉栓塞术后肝脏功能的应用价值［J］. 中华消化外科杂志，2021，20（7）:822-827. DOI:10.37 60/cma.j.cn115610-20210413-00183.
|
| ［106］ |
Denys A， Bize P， Demartines N， et al. Quality improvement for portal vein embolization［J］. Cardiovasc Intervent Radiol， 2010，33（3）:452-456. DOI:10.1007/s00270-009-9737-x.
|
| ［107］ |
de Graaf W， van Lienden KP， van den Esschert JW， et al. Increase in future remnant liver function after preoperative portal vein embolization［J］. Br J Surg，2011，98（6）:825-834. DOI:10.1002/bjs.7456.
|
| ［108］ |
Rassam F， Olthof PB， van Lienden KP， et al. Functional and volumetric assessment of liver segments after portal vein embolization: differences in hypertrophy response［J］. Surgery，2019，165（4）:686-695. DOI:10.1016/j.surg.2018.11.004.
|
| ［109］ |
Panaro F， Giannone F， Riviere B， et al. Perioperative impact of liver venous deprivation compared with portal venous embolization in patients undergoing right hepatectomy: preliminary results from the pioneer center［J］. Hepatobiliary Surg Nutr， 2019， 8（4）: 329-337. DOI:10.21037/hbsn. 2019.07.06.
|
| ［110］ |
Kobayashi K， Yamaguchi T， Denys A， et al. Liver venous deprivation compared to portal vein embolization to induce hypertrophy of the future liver remnant before major hepatectomy: a single center experience［J］. Surgery， 2020， 167 （6）:917-923. DOI:10.1016/j.surg.2019.12.006.
|
| ［111］ |
Jiang N， Wang SY， Xiang CH， et al. Patterns of caudate lobe invasion of hilar cholangiocarcinoma: a panoramic histologic study of liver［J］.Ann Surg Oncol，2022，29（11）:6804-6812. DOI:10.1245/s10434-022-11964-9.
|
| ［112］ |
Nagino M， Hirano S， Yoshitomi H， et al. Clinical practice guidelines for the management of biliary tract cancers 2019: the 3rd english edition［J］. J Hepatobiliary Pancreat Sci，2021，28（1）:26-54.DOI:10.1002/jhbp.870.
|
| ［113］ |
Ishii T， Seo S， Ito T， et al. Liver transection-first approach in hepatopancreatoduodenectomy for hilar cholangiocarcinoma: a safe and secure technique for the early assessment of curable resection and vascular reconstruction［J］. Ann Surg Oncol，2021，28（6）:2988-2989.DOI: 10.1245/s10 434-020-09303-x.
|
| ［114］ |
Nimura Y， Hayakawa N， Kamiya J， et al. Hepatic segmentectomy with caudate lobe resection for bile duct carcinoma of the hepatic hilus［J］.World J Surg，1990，14（4）:535-544. DOI: 10.1007/BF01658686.
|
| ［115］ |
Yamamoto H， Hayakawa N， Komatsu S， et al. Right hepatic lobectomy and subsegmental resection of the left caudate lobe for gallbladder carcinoma involving the hepatic hilus: preservation of the ventral portion of the left caudate lobe［J］. J Hepatobiliary Pancreat Surg，1998，5（2）:207-211. DOI: 10.1007/s005340050035.
|
| ［116］ |
Nagino M， Kamiya J， Arai T， et al. “Anatomic” right hepatic trisectionectomy （extended right hepatectomy） with caudate lobectomy for hilar cholangiocarcinoma［J］. Ann Surg， 2006， 243（1）:28-32. DOI: 10.1097/01.sla.0000193604.72436.63.
|
| ［117］ |
Bhutiani N， Scoggins CR， McMasters KM， et al. The impact of caudate lobe resection on margin status and outcomes in patients with hilar cholangiocarcinoma: a multi-institutional analysis from the US extrahepatic biliary malignancy consortium［J］.Surgery，2018，163（4）:726-731. DOI:10.1016/ j.surg.2017.10.028.
|
| ［118］ |
Hu YF， Hu HJ， Lv TR， et al. Should more aggressive surgical resection be considered in the treatment for Bismuth types Ⅰ and II hilar cholangiocarcinoma？ A meta-analysis［J］. Asian J Surg， 2023，46（10）: 4115-4123. DOI: 10.1016/j.asjsur.2022.12.043.
|
| ［119］ |
Shimizu H， Kimura F， Yoshidome H， et al. Aggressive surgical resection for hilar cholangiocarcinoma of the left-side predominance:radicality and safety of left-sided hepatectomy［J］. Ann Surg， 2010，251（2）: 281-286. DOI: 10.1097/ SLA.0b013e3181be0085.
|
| ［120］ |
Govil S， Bharatan A， Rammohan A， et al. Liver resection for perihilar cholangiocarcinoma why left is sometimes right［J］. HPB（Oxford），2016，18（7）:575-579. DOI:10.1016/ j.hpb.2016.05.002.
|
| ［121］ |
Hartog H， Ijzermans JN， van Gulik TM， et al. Resection of perihilar cholangiocarcinoma［J］. Surg Clin North Am，2016， 96（2）:247-267.DOI:10.1016/j.suc.2015.12.008.
|
| ［122］ |
Nishio H， Nagino M， Nimura Y. Surgical management of hilar cholangiocarcinoma: the Nagoya experience［J］. HPB （Oxford），2005，7（4）:259-262. DOI:10.1080/13651820500 373010.
|
| ［123］ |
Kovalenko YA， Zharikov YO， Konchina NA， et al. Perihilar cholangiocarcinoma: a different concept for radical resection［J］. Surg Oncol， 2020， 33: 270-275. DOI: 10.1016/j. sur onc.2020.02.013.
|
| ［124］ |
Capussotti L， Vigano L， Ferrero A， et al. Local surgical resection of hilar cholangiocarcinoma: is there still a place？［J］. HPB（Oxford），2008，10（3）:174-178. DOI:10.1080/136518 20801992534.
|
| ［125］ |
Hirano S， Tanaka E， Shichinohe T， et al. Treatment strategy for hilar cholangiocarcinoma， with special reference to the limits of ductal resection in right-sided hepatectomies［J］. J Hepatobiliary Pancreat Surg，2007，14（5）:429-433. DOI: 10.1007/s00534-006-1190-5.
|
| ［126］ |
Masunari H， Shimada H， Endo I， et al. Surgical anatomy of hepatic hilum with special reference of the plate system and extrahepatic duct［J］. J Gastrointest Surg，2008，12（6）: 1047-1053. DOI:10.1007/s11605-007-0358-x.
|
| ［127］ |
Kim JH， Kim H. Pure laparoscopic anatomical segment Ⅴresection using the extrafascial and transfissural Glissonean Approach［J］. Ann Surg Oncol，2019，26（7）:2241. DOI:10.12 45/s10434-019-07324-9.
|
| ［128］ |
Wahab MA， Sultan AM， Salah T， et al. Caudate lobe resection with major hepatectomy for central cholangiocarcinoma: is it of value？［J］.Hepatogastroenterology， 2012， 59 （114）: 321-324. DOI: 10.5754/hge11999.
|
| ［129］ |
Wang S， Tian F， Zhao X， et al. A new surgical procedure “dumbbell-form resection” for selected hilar cholangiocarcinomas with severe jaundice:comparison with hemihepatectomy［J］. Medicine （Baltimore）， 2016，95（2）: e2456. DOI:10.1097/MD.0000000000002456.
|
| ［130］ |
Perini MV， Coelho FF， Kruger JA， et al. Extended right hepatectomy with caudate lobe resection using the hilar “en bloc” resection technique with a modified hanging maneuver［J］. J Surg Oncol， 2016，113（4）: 427-431. DOI: 10.1002/ jso.24154.
|
| ［131］ |
Capussotti L， Viganò L. Local resection without hepatectomy//Lau W.Hilar cholangiocarcinoma［M］. Dordrecht: Springer，2013.
|
| ［132］ |
Gavriilidis P， Askari A， Roberts KJ， et al. Appraisal of the current guidelines for management of cholangiocarcinomausing the appraisal of guidelines research and evaluation Ⅱ （AGREE Ⅱ） instrument［J］.Hepatobiliary Surg Nutr，2020， 9（2）:126-135. DOI:10.21037/hbsn.2019.09.06.
|
| ［133］ |
Molina V， Sampson J， Ferrer J， et al. Surgical treatment of perihilar cholangiocarcinoma: early results of en bloc portal vein resection［J］.Langenbecks Arch Surg，2017，402（1）: 95-104. DOI:10.1007/s00423-016-1542-9.
|
| ［134］ |
Higuchi R， Yazawa T， Uemura S， et al. Surgical outcomes for perihilar cholangiocarcinoma with vascular invasion［J］. J Gastrointest Surg，2019，23（7）:1443-1453. DOI:10.10 07/s11605-018-3948-x.
|
| ［135］ |
Nagino M， Nimura Y， Nishio H， et al. Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases［J］. Ann Surg，2010，252（1）:115-123. DOI: 10.1097/SLA.0b013e3181e463a7.
|
| ［136］ |
D’ Souza MA， Valdimarsson VT， Campagnaro T， et al.Hepatopancreatoduodenectomya controversial treatment for bile duct and gallbladder cancer from a European perspective［J］. HPB（Oxford）， 2020， 22（9）: 1339-1348. DOI: 10. 1016/j.hpb.2019.12.008.
|
| ［137］ |
Nishio H， Nagino M， Nimura Y. Surgical management of hilar cholangiocarcinoma: the Nagoya experience［J］. HPB（Oxford），2005，7（4）:259-262. DOI:10.1080/13651820500 373010.
|
| ［138］ |
Schimizzi GV， Jin LX， Davidson JT 4th， et al. Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium［J］. HPB （Oxford），2018，20（4）:332-339. DOI:10.1016/j.hpb.2017.10.003.
|
| ［139］ |
Matsuyama R， Mori R， Ota Y， et al. Significance of vascular resection and reconstruction in surgery for hilar cholangiocarcinoma: with special reference to hepatic arterial resection and reconstruction［J］.Ann Surg Oncol， 2016， 23 （Suppl 4）:475-484. DOI:10.1245/s10434-016-5381-2.
|
| ［140］ |
Chen KJ， Yang FC， Qin YS， et al. Assessment of clinical outcomes of advanced hilar cholangiocarcinoma［J］. Hepatobiliary Pancreat Dis Int，2018，17（2）:155-162. DOI:10.1016/j.hbpd. 2018.03.003.
|
| ［141］ |
Fancellu A， Sanna V， Deiana G， et al. Current role of hepatopancreatoduodenectomy for the management of gallbladder cancer and extrahepatic cholangiocarcinoma: a systematic review［J］.World J Gastrointest Oncol，2021，13（6）:625-637. DOI:10.4251/wjgo.v13.i6.625.
|
| ［142］ |
Nagino M. Fifty-year history of biliary surgery［J］. Ann Gastroenterol Surg，2019，3（6）:598-605. DOI:10.1002/ags3. 12289.
|
| ［143］ |
Ebata T， Yokoyama Y， Igami T， et al. Hepatopancreatoduodenectomy for cholangiocarcinoma: a single-center review of 85 consecutive patients［J］. Ann Surg，2012，256（2）:297-305. DOI:10.1097/SLA.0b013e31826029ca.
|
| ［144］ |
Aoki T， Sakamoto Y， Kohno Y， et al. Hepatopancreaticoduodenectomy for biliary cancer: strategies for near-zero operative mortality and acceptable long-term outcome［J］. Ann Surg，2018，267（2）:332-337.DOI:10.1097/SLA.00000000 00002059.
|
| ［145］ |
He YG， Huang W， Ren Q， et al. Comparison of efficacy and safety between laparoscopic and open radical resection for hilar cholangiocarcinoma-a propensity score-matching analysis［J］. Front Oncol， 2022， 12: 1004974. DOI: 10.3389/ fonc.2022.1004974.
|
| ［146］ |
Ratti F， Fiorentini G， Cipriani F， et al. Perihilar cholangiocarcinoma:are we ready to step towards minimally invasiveness？［J］. Updates Surg，2020，72（2）:423-433. DOI:10. 1007/s13304-020-00752-3.
|
| ［147］ |
Wang J， Xia Y， Cao Y， et al. Safety and feasibility of laparoscopic radical resection for bismuth types Ⅲ and Ⅳ hilar cholangiocarcinoma:a single-center experience from China［J］. Front Oncol，2023，13:1280513. DOI:10.3389/fonc.2023. 1280513.
|
| ［148］ |
Xiong F， Peng F， Li X， et al. Preliminary comparison of total laparoscopic and open radical resection for hepatic hilar cholangiocarcinoma a single-center cohort study［J］. Asian J Surg，2023，46（2）:856-862. DOI:10.1016/j.asjsur.2022. 07.158.
|
| ［149］ |
Zhang J， Qiao QL， Guo XC， et al. Application of three-dimensional visualization technique in preoperative planning of progressive hilar cholangiocarcinoma［J］. Am J Transl Res， 2018，10（6）:1730-1735.
|
| ［150］ |
腹腔镜肝门部胆管癌根治切除术操作规范专家组，中华外科杂志编辑部. 腹腔镜肝门部胆管癌根治性切除操作流程专家建议［J］. 中华外科杂志，2019，57（8）:561-567. DOI:10. 3760/cma.j.issn.0529-5815.2019.08.001.
|
| ［151］ |
Giulianotti PC， Coratti A， Sbrana F， et al. Robotic liver surgery:results for 70 resections［J］. Surgery，2011，149（1）:29-39. DOI:10.1016/j.surg.2010.04.002.
|
| ［152］ |
Knitter S， Feldbrügge L， Nevermann N， et al. Robotic versus laparoscopic versus open major hepatectomy-an analysis of costs and postoperative outcomes in a single-center setting［J］. Langenbecks Arch Surg， 2023， 408（1）: 214. DOI: 10.1007/s00423-023-02953-x.
|
| ［153］ |
Xu Y， Wang H， Ji W， et al. Robotic radical resection for hilar cholangiocarcinoma: perioperative and long-term outcomes of an initial series［J］. Surg Endosc， 2016， 30（7）: 3060-3070. DOI: 10.1007/s00464-016-4925-7.
|
| ［154］ |
Wang W， Fei Y， Liu J， et al. Laparoscopic surgery and robotic surgery for hilar cholangiocarcinoma: an updated systematic review［J］. ANZ J Surg，2021，91（1/2）:42-48. DOI: 10.1111/ans.15948.
|
| ［155］ |
Robles R， Sánchez-Bueno F， Ramírez P， et al. Liver transplantation for hilar cholangiocarcinoma［J］. World J Gastroenterol， 2013， 19（48）:9209-9215. DOI: 10.3748/wjg. v19.i48.9209.
|
| ［156］ |
Azad AI， Rosen CB， Taner T， et al. Selected patients with unresectable perihilar cholangiocarcinoma （pCCA） derive long-term benefit from liver transplantation［J］. Cancers （Basel），2020，12（11）:3157.DOI:10.3390/cancers12113157.
|
| ［157］ |
Rea DJ， Heimbach JK， Rosen CB， et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma［J］. Ann Surg， 2005， 242（3）: 451-461. DOI:10.1097/01. sla. 0000179678. 13285.fa.
|
| ［158］ |
Gores GJ， Darwish Murad S， Heimbach JK， et al. Liver transplantation for perihilar cholangiocarcinoma［J］. Dig Dis，2013，31（1）:126-129. DOI:10.1159/000347207.
|
| ［159］ |
Duignan S， Maguire D， Ravichand CS， et al. Neoadjuvant chemoradiotherapy followed by liver transplantation for unresectable cholangiocarcinoma: a single-centre national experience［J］. HPB（Oxford），2014，16（1）:91-98. DOI:10.11 11/hpb.12082.
|
| ［160］ |
Darwish Murad S， Heimbach JK， Gores GJ， et al. Excellent quality of life after liver transplantation for patients with perihilar cholangiocarcinoma who have undergone neoadjuvant chemoradiation［J］. Liver Transpl，2013，19（5）:521-528. DOI:10.1002/lt.23630.
|
| ［161］ |
Zaborowski A， Heneghan HM， Fiore B， et al. Neoadjuvant chemoradiotherapy and liver transplantation for unresectable hilar cholangiocarcinoma: the Irish experience of the Mayo protocol［J］. Transplantation，2020，104（10）:2097-2104. DOI:10.1097/TP.0000000000003114.
|
| ［162］ |
Croome KP， Rosen CB， Heimbach JK， et al. Is liver transplantation appropriate for patients with potentially resectable de novo hilar cholangiocarcinoma？［J］. J Am Coll Surg，2015， 221（1）:130-139.DOI:10.1016/j.jamcollsurg.2015.01.064.
|
| ［163］ |
Moris D， Kostakis ID， Machairas N， et al. Comparison between liver transplantation and resection for hilar cholangiocarcinoma:a systematic review and meta-analysis［J］. PLoS One，2019，14（7）:e0220527. DOI:10.1371/journal.pone.0220527.
|
| ［164］ |
Jung JH， Lee HJ， Lee HS， et al. Benefit of neoadjuvant concurrent chemoradiotherapy for locally advanced perihilar cholangiocarcinoma［J］.World J Gastroenterol，2017，23（18）: 3301-3308. DOI:10.3748/wjg.v23.i18.3301.
|
| ［165］ |
Matsuyama R， Mori R， Ota Y， et al. Impact of gemcitabine plus S1 neoadjuvant chemotherapy on borderline resectable perihilar cholangiocarcinoma［J］. Ann Surg Oncol，2022， 29（4）:2393-2405.DOI:10.1245/s10434-021-11206-4.
|
| ［166］ |
Kuriyama N， Usui M， Gyoten K， et al. Neoadjuvant chemotherapy followed by curative-intent surgery for perihilar cholangiocarcinoma based on its anatomical resectability classification and lymph node status［J］. BMC Cancer，2020， 11，20（1）:405. DOI:10.1186/s12885-020-06895-1.
|
| ［167］ |
Valle J， Wasan H， Palmer DH， et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer［J］. N Engl J Med， 2010， 362（14）:1273-1281. DOI: 10.1056/NEJMoa0908721.
|
| ［168］ |
Oh DY， Ruth He A， Qin S， et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer［J］. NEJM Evid，2022，1（8）:EVIDoa2200015. DOI:10.1056/EVIDoa220 0015.
|
| ［169］ |
Kelley RK， Ueno M， Yoo C， et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer（KEYNOTE-966）: a randomised， doubleblind， placebo-controlled，phase 3 trial［J］. Lancet，2023，401 （10391）:1853-1865. DOI:10.1016/S0140-6736（23）00727-4.
|
| ［170］ |
Morizane C， Okusaka T， Mizusawa J， et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT （JCOG1113） randomized phase Ⅲclinical trial［J］. Ann Oncol， 2019， 30 （12）:1950-1958. DOI:10.1093/annonc/mdz402.
|
| ［171］ |
Kim ST， Kang JH， Lee J， et al. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter， open-label， randomized， phase Ⅲ，noninferiority trial［J］. Ann Oncol， 2019，30（5）:788-795. DOI:10.1093/annonc/mdz058.
|
| ［172］ |
Ioka T， Kanai M， Kobayashi S， et al. Randomized phase Ⅲ study of gemcitabine， cisplatin plus S-1 versus gemcitabine， cisplatin for advanced biliary tract cancer （KHBO1401-MITSUBA）［J］. J Hepatobiliary Pancreat Sci，2023，30（1）:102-110. DOI:10.1002/jhbp.1219.
|
| ［173］ |
Fiteni F， Nguyen T， Vernerey D， et al. Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review［J］. Cancer Med， 2014，3（6）:1502-1511.DOI:10.1002/cam4.299.
|
| ［174］ |
Sahai V， Catalano PJ， Zalupski MM， et al. Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: a phase 2 clinical trial［J］. JAMA Oncol，2018，4（12）:1707-1712. DOI:10.1001/jamaoncol.2018. 3277.
|
| ［175］ |
Lamarca A， Palmer DH， Wasan HS， et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer （ABC-06）: a phase 3， open-label， randomised， controlled trial［J］. Lancet Oncol， 2021， 22（5）: 690-701. DOI:10.1016/S1470-2045（21）00027-9.
|
| ［176］ |
Yoo C， Kim KP， Jeong JH， et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin（NIFTY）: a multicentre， open-label， randomised， phase 2b study［J］.Lancet Oncol， 2021， 22（11）:1560-1572. DOI:10.1016/S1470-2045（21）00486-1.
|
| ［177］ |
Zheng Y， Tu X， Zhao P， et al. A randomised phase Ⅱ study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin［J］. Br J Cancer，2018，119 （3）:291-295. DOI:10.1038/s41416-018-0138-2.
|
| ［178］ |
Caparica R， Lengelé A， Bekolo W， et al. FOLFIRI as second-line treatment of metastatic biliary tract cancer patients［J］. Autops Case Rep， 2019， 9（2）: e2019087. DOI: 10.4322/ acr.2019.087.
|
| ［179］ |
Javle M， Borad MJ， Azad NS， et al. Pertuzumab and trastuzumab for HER2-positive， metastatic biliary tract cancer （MyPathway）:a multicentre， open-label， phase 2a， multiple basket study［J］.Lancet Oncol， 2021， 22（9）: 1290-1300. DOI: 10.1016/S1470-2045（21）00336-3.
|
| ［180］ |
Ohba A， Morizane C， Kawamoto Y， et al. Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer （HERB； NCCH1805）: a multicenter， single-arm， phaseⅡ trial［J］. J Clin Oncol，2024，42（27）:3207-3217. DOI:10.1200/JCO.23.02010.
|
| ［181］ |
Harding JJ， Fan J， Oh DY， et al. Zanidatamab for HER2-amplified，unresectable， locally advanced or metastatic biliary tract cancer（HERIZON-BTC-01）: a multicentre， single-arm， phase 2b study［J］. Lancet Oncol，2023，24（7）:772-782. DOI: 10.1016/S1470-2045（23）00242-5.
|
| ［182］ |
Doebele RC， Drilon A， Paz-Ares L， et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials［J］. Lancet Oncol，2020，21（2）:271-282. DOI:10.1016/S1470-2045（19）30691-6.
|
| ［183］ |
Drilon A， Laetsch TW， Kummar S， et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children［J］. N Engl J Med，2018，378（8）:731-739. DOI:10.1056/NEJ Moa1714448.
|
| ［184］ |
Subbiah V， Cassier PA， Siena S， et al. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial［J］. Nat Med，2022，28（8）: 1640-1645.DOI:10.1038/s41591-022-01931-y.
|
| ［185］ |
Subbiah V， Wolf J， Konda B， et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusionpositive solid tumours other than lung or thyroid tumours （LIBRETTO-001）:a phase 1/2， open-label， basket trial［J］. Lancet Oncol，2022，23（10）:1261-1273. DOI:10.1016/S14 70-2045（22）00541-1.
|
| ［186］ |
Ou SI， Jänne PA， Leal TA， et al. First-in-human phase Ⅰ/ⅠB dose-finding study of adagrasib （MRTX849） in patients with advanced KRAS（G12C） solid tumors （KRYSTAL-1）［J］. J Clin Oncol，2022，40（23）:2530-2538. DOI:10.1200/JCO.21. 02752.
|
| ［187］ |
Abou-Alfa GK， Macarulla T， Javle MM， et al. Ivosidenib in IDH1-mutant， chemotherapy-refractory cholangiocarcinoma （ClarIDHy）:a multicentre， randomised， double-blind， placebo-controlled， phase 3 study［J］. Lancet Oncol，2020，21（6）:796-807. DOI:10.1016/S1470-2045（20）30157-1.
|
| ［188］ |
Abou-Alfa GK， Sahai V， Hollebecque A， et al. Pemigatinib for previously treated， locally advanced or metastatic cholangiocarcinoma:a multicentre， open-label， phase 2 study［J］. Lancet Oncol， 2020，21（5）: 671-684. DOI: 10.1016/S1470-2045（20）30109-1.
|
| ［189］ |
Subbiah V， Lassen U， Élez E， et al. Dabrafenib plus trametinib in patients with BRAF（V600E）-mutated biliary tract cancer （ROAR）:a phase 2， open-label， single-arm， multicentre basket trial［J］. Lancet Oncol，2020，21（9）:1234-1243. DOI:10.1016/S1470-2045（20）30321-1.
|
| ［190］ |
Zhou J， Sun Y， Zhang W， et al. Phase Ⅰb study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis［J］. Hepatology， 2023， 77（1）:65-76. DOI:10.1002/hep.32548.
|
| ［191］ |
Yarchoan M， Cope L， Ruggieri AN， et al. Multicenter randomized phase Ⅱ trial of atezolizumab with or without cobimetinib in biliary tract cancers［J］. J Clin Invest，2021， 131（24）:e152670. DOI:10.1172/JCI152670.
|
| ［192］ |
Cousin S， Cantarel C， Guegan JP， et al. Regorafenib-avelumab combination in patients with biliary tract cancer （REGOMUNE）: a single-arm， open-label， phaseⅡ trial［J］. Eur J Cancer， 2022，162:161-169. DOI:10.1016/j.ejca.2021. 11.012.
|
| ［193］ |
Piha-Paul SA， Oh DY， Ueno M， et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies［J］. Int J Cancer，2020，147（8）:2190-2198. DOI:10. 1002/ijc.33013.
|
| ［194］ |
André T， Berton D， Curigliano G， et al. Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial［J］. JAMA Netw Open，2023， 6（11）: e2341165. DOI:10.1001/jamanetworkopen.2023.41165.
|
| ［195］ |
Bridgewater J， Fletcher P， Palmer DH， et al. Long-term outcomes and exploratory analyses of the randomized phase Ⅲ BILCAP study［J］. J Clin Oncol，2022，40（18）:2048-2057. DOI: 10.1200/JCO.21.02568.
|
| ［196］ |
Nakachi K， Ikeda M， Konishi M， et al. Adjuvant S-1 compared with observation in resected biliary tract cancer （JCOG1202，ASCOT）: a multicentre， open-label， randomised， controlled， phase 3 trial［J］. Lancet，2023，401（10372）: 195-203. DOI:10.1016/S0140-6736（22）02038-4.
|
| ［197］ |
Ben-Josef E， Guthrie KA， El-Khoueiry AB， et al. SWOG S0809: a phase Ⅱ Intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma［J］. J Clin Oncol，2015，33（24）:2617-2622. DOI:10.1200/JCO.2014.60.2219.
|
| ［198］ |
Ren B， Guo Q， Yang Y， et al. A meta-analysis of the efficacy of postoperative adjuvant radiotherapy versus no radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma［J］.Radiat Oncol，2020，15（1）:15. DOI:10. 1186/s13014-020-1459-x.
|
| ［199］ |
Li HM， Dou KF， Sun K， et al. Palliative surgery for hilar cholangiocarcinoma［J］. Hepatobiliary Pancreat Dis Int，2003， 2（1）:110-113.
|
| ［200］ |
Almadi MA， Barkun A， Martel M. Plastic vs. Self-expandable metal stents for palliation in malignant biliary obstruction: a series of metaanalyses［J］. Am J Gastroenterol， 2017，112（2）:260-273. DOI:10.1038/ajg.2016.512.
|
| ［201］ |
Wei Z， Wang Y， Wu B， et al. Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma［J］. Front Immunol，2023，14:1235724. DOI:10.3389/ fimmu.2023.1235724.
|
| ［202］ |
Wang T， Dong J， Zhang Y， et al. Efficacy and safety of hepatic artery infusion chemotherapy with mFOLFOX in primary liver cancer patients with hyperbilirubinemia and ineffective drainage:a retrospective cohort study［J］. Ann Transl Med，2022，10（7）:411.DOI:10.21037/atm-22-978.
|
| ［203］ |
Chen P， Yang T， Shi P， et al. Benefits and safety of photodynamic therapy in patients with hilar cholangiocarcinoma: a meta-analysis［J］.Photodiagnosis Photodyn Ther，2022， 37:102712. DOI:10.1016/j.pdpdt.2022.102712.
|
| ［204］ |
Borghero Y， Crane CH， Szklaruk J， et al. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone［J］.Ann Surg Oncol， 2008，15（11）:3147-3156. DOI:10.1245/s10434-008-9998-7.
|
| ［205］ |
Tang Z， Yang Y， Zhao Z， et al. The clinicopathological factors associated with prognosis of patients with resectable perihilar cholangiocarcinoma: a systematic review and meta-analysis［J］.Medicine （Baltimore），2018，97（34）:e11999. DOI: 10.1097/MD.0000000000011999.
|
| ［206］ |
Bird N， McKenna A， Dodd J， et al. Meta-analysis of prognostic factors for overall survival in patients with resected hilar cholangiocarcinoma［J］. Br J Surg， 2018， 105（11）: 1408-1416. DOI:10.1002/bjs.10921.
|
| ［207］ |
Liang L， Li C， Jia HD， et al. Prognostic factors of resectable perihilar cholangiocarcinoma: a systematic review and meta-analysis of high-quality studies［J］. Ther Adv Gastrointest Endosc，2021，14:2631774521993065. DOI:10.1177/2631774521993065.
|
| ［208］ |
Komaya K， Ebata T， Yokoyama Y， et al. Recurrence after curativeintent resection of perihilar cholangiocarcinoma: analysis of a large cohort with a close postoperative followup approach［J］.Surgery，2018，163（4）:732-738. DOI:10.10 16/j.surg.2017.08.011.
|
| ［209］ |
Hu HJ， Mao H， Shrestha A， et al. Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: a single-institution experience in China［J］. World J Gastroenterol， 2016，22（8）:2601-2610.DOI:10.3748/wjg.v22.i8.2601.
|
| ［210］ |
Cai JQ， Cai SW， Cong WM， et al. Diagnosis and treatment of cholangiocarcinoma: a consensus from surgical specialists of China［J］. J Huazhong Univ Sci Technolog Med Sci，2014， 34（4）:469-475. DOI:10.1007/s11596-014-1301-5.
|